Sign in

OMER on Nasdaq

OMEROS CORP

OMEROS CORP is an American pharmaceutical preparations company based in Seattle.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Bicycle Therapeutics (United Kingdom), AbCellera Biologics Inc. or ASSEMBLY BIOSCIENCES, INC., or pick any stock.

  • TickerOMER on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersSeattle, United States2
  • Incorporated inWA3
  • Business address201 Elliott Avenue West, Seattle, Wa 981193
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formProfit Corporation2
  • LEI549300CJWLXX2MXVVV712
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O REGISTERED AGENT SOLUTIONS, INC., 98501 Tumwater, United States2
  • Registered withCorporations Division (Office of the Secretary of State), 601 553 2682

See how the biggest companies compare on our leaderboards

Omeros Corporation (“Omeros,” the “Company” or “we”) is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-212.6%Operating margin5
-187.0%Net margin5
-34.0%Revenue growth, 20206
-$100.4MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Cost of revenue1¢$902.0K
  • Research and development68¢$107.6M
  • Interest17¢$26.8M
  • Income tax15¢$23.3M

Out of $73.8M in revenue.65 The company lost money this year.

Financial statements

Revenue6$73.8M in 2020−34% since 2019
0$50.0M$100.0M$150.0M2019: $111.8M$111.8M20192020: $73.8M$73.8M2020−34%
Operating income75-$156.9M in 2020+7% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$146.0M-$146.0M20192020: -$156.9M-$156.9M2020+7%
Net income75-$138.1M in 2020+63% since 2019
-$150.0M-$100.0M-$50.0M02019: -$84.5M-$84.5M20192020: -$138.1M-$138.1M2020+63%

Every line of the income statement as filed: the last 3 fiscal years, latest first.10

Period ending2025-12-312024-12-312023-12-31
Research and development$81.3M$119.5M$114.9M
Selling, general and administrative$41.5M$47.4M$49.7M
Total costs and expenses$122.8M$167.0M$164.5M
Loss from operations-$122.8M-$167.0M-$164.5M
Gain on sale of zaltenibart$237.6M$0$0
Interest and other income$4.1M$11.3M$16.3M
Interest expense, net of remeasurement adjustments and other$960.0K-$24.7M-$30.8M
Gain (loss) on change in fair value of financial instruments, net-$136.7M$19.0K$0
Loss from continuing operations before income tax expense-$2.8M-$180.3M-$174.9M
Income tax expense-$2.0M-$2.3M$0
Net loss from continuing operations, net of tax-$4.8M-$182.6M-$174.9M
Net income from discontinued operations, net of tax$1.5M$25.8M$57.1M
Net loss-$3.4M-$156.8M-$117.8M
Net loss from continuing operations (in dollars per share)-$0-$3-$3
Net loss from continuing operations (in dollars per share)-$0-$3-$3
Net income from discontinued operations (in dollars per share)$0$0$1
Net income from discontinued operations (in dollars per share)$0$0$1
Net loss (in dollars per share)-$0.05-$2.70-$1.88
Net loss (in dollars per share)-$0.05-$2.70-$1.88
Weighted-average shares used to compute basic and diluted net income (loss) per share (in shares)63.5M shares58.2M shares62.7M shares

Compare OMEROS CORP with another company

Corporate structure

OMEROS CORP sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of OMEROS CORP

  • OMEROS CORP Seattle, Washington, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What OMEROS CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$13.8M10 Dec 31, 2025$13.8M10 Dec 31, 2024+0.4%
Accumulated depreciation$12.0M10 Dec 31, 2025$11.1M10 Dec 31, 2024+8.7%
Property and equipment, net$1.8M10 Dec 31, 2025$2.7M10 Dec 31, 2024−34.0%
Finance-lease assets$1.3M10 Dec 31, 2025$2.0M10 Dec 31, 2024−36.4%
Operating-lease assets (leased space)$10.7M10 Dec 31, 2025$15.0M10 Dec 31, 2024−28.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$9.7M10 Dec 31, 2025$3.4M10 Dec 31, 2024+184.1%
Marketable securities, current$162.1M10 Dec 31, 2025$86.7M10 Dec 31, 2024+86.9%

Properties, in its own words

We lease approximately 106,949 square feet for our principal office and laboratory space in the building located at 201 Elliott Avenue West, Seattle, Washington (the Omeros Building), which includes 1,134 square feet of laboratory space that we are subleasing to third parties. The lease term for our space is through November 2027. We also have two options to extend the lease term, each by five years. The annual base rent due under the lease for our principal office and laboratory space is $6.6 million for 2026, and $5.7 million for 2027. In addition, we are responsible for paying our proportionate share of the building’s utilities, taxes, insurance and maintenance as well as a property management fee.

We believe that our facilities are sufficient for our anticipated near-term needs.

Item 2 of the 10-K filed Mar 31, 2026.4

Leadership

Who has led OMEROS CORP, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gregory A. Demopulos Md.2010–now

Chair

  1. Gregory A. Demopulos Md.2010–now

President

  1. Gregory A. Demopulos Md.2010–now
2010201520202025
Board members and other officers (18)

Timeline

  1. Aug 13, 20268-K Executive or director change30
  2. Aug 12, 20268-K Results of operations31
  3. Jul 20, 20268-K Other events32
  4. Jul 6, 20268-K Other events33
  5. Jun 25, 20268-K Shareholder vote34
  6. Jun 18, 20268-K Other events35
  7. May 13, 20268-K Results of operations36
  8. Mar 31, 20268-K Results of operations37
  9. Jan 7, 20268-K Results of operations38
  10. Dec 29, 20258-K Other events39
  11. Dec 1, 20258-K Ended a material agreement; Completed an acquisition or sale; Other events40
  12. Nov 13, 20258-K Results of operations41
  13. Apr 9, 2010New chief executive Gregory A. Demopulos Md. becomes CEO12
  14. Jun 16, 1994Founded OMEROS CORP is founded2

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.19) a share, on Nov 13, 2025.42

When it reported results

  1. Aug 12, 2026Reported quarterly or annual results31
  2. May 13, 2026Reported quarterly or annual results36
  3. Mar 31, 2026Reported quarterly or annual results37
  4. Jan 7, 2026Reported quarterly or annual results38
  5. Nov 13, 2025Reported quarterly or annual results41
  6. Aug 14, 2025Reported quarterly or annual results43
  7. May 15, 2025Reported quarterly or annual results44
  8. Mar 31, 2025Reported quarterly or annual results45

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

213 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 49 major events, 85 insider forms, 19 large holders, 38 other. The latest 20:

  1. Sep 24, 20264 EDGAR
  2. Sep 23, 2026144 EDGAR
  3. Sep 22, 2026144 EDGAR
  4. Sep 1, 20264 EDGAR
  5. Aug 31, 2026144 EDGAR
  6. Aug 28, 2026144 EDGAR
  7. Aug 28, 20264 EDGAR
  8. Aug 27, 2026144 EDGAR
  9. Aug 26, 2026144 EDGAR
  10. Aug 25, 20264 EDGAR
  11. Aug 21, 2026144 EDGAR
  12. Aug 21, 20264 EDGAR
  13. Aug 20, 2026144 EDGAR
  14. Aug 18, 20264 EDGAR
  15. Aug 18, 20263 EDGAR
  16. Aug 17, 20264 EDGAR
  17. Aug 13, 2026144 EDGAR
  18. Aug 13, 2026S-8 EDGAR
  19. Aug 13, 20268-K EDGAR
  20. Aug 12, 202610-Q EDGAR

The 213 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

17 open-market trades by officers, directors and large owners since October 2021: 2 buys and 15 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 23, 2026Borges David J.VP, Finance & CAOSale10,000$20.95$209.5KForm 4
Sep 22, 2026Borges David J.VP, Finance & CAOSale10,000$20.95$209.5KForm 4
Aug 31, 2026Cancelmo Peter BVP, General CounselSale25,000$18.54$463.5KForm 4
Aug 28, 2026Cancelmo Peter BVP, General CounselSale25,000$18.65$466.2KForm 4
Aug 27, 2026HANISH ARNOLD CDirectorSale10,000$18.95$189.5KForm 4
Aug 26, 2026HANISH ARNOLD CDirectorSale5,000$18.53$92.7KForm 4
Aug 24, 2026Borges David J.VP, Finance & CAOSale906$19.10$17.3KForm 4
Aug 21, 2026Borges David J.VP, Finance & CAOSale10,000$18.95$189.5KForm 4
Aug 20, 2026Cable Thomas J.DirectorSale15,000$18.45$276.8KForm 4
Aug 13, 2026Borges David J.VP, Finance & CAOSale5,000$16.95$84.8KForm 4
May 22, 2026Cable Thomas J.DirectorSale7,500$11.61$87.1KForm 4
Jan 13, 2026Borges David J.VP, Finance & CAOSale30,000$12.31$369.3KForm 4
Jan 12, 2026Borges David J.VP, Finance & CAOSale30,000$12.72$381.6KForm 4
Nov 17, 2023Demopulos Gregory A MDChairman, CEO & PresidentBuy15,000$1.68$25.2KForm 4
Nov 15, 2023Demopulos Peter A MDDirectorBuy10,000$1.53$15.3KForm 4
May 22, 2023HANISH ARNOLD CDirectorSale5,000$6.46$32.3KForm 4
May 22, 2023Cable Thomas J.DirectorSale5,000$6.53$32.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Gregory A. Demopulos, M.D.President, Chief Executive Officer and Chairman of the Board$972.5K$4.2M51
2025Peter B. Cancelmo, J.D.Vice President, General Counsel and Secretary$489.5K$920.7K51
2025David J. BorgesVice President, Finance, Chief Accounting Officer and Treasurer$325.6K$686.3K51
2024Gregory A. Demopulos, M.D.President, Chief Executive Officer and Chairman of the Board$960.9K$3.8M51
2024Peter B. Cancelmo, J.D.Vice President, General Counsel and Secretary$483.7K$906.9K51
2024David J. BorgesVice President, Finance, Chief Accounting Officer and Treasurer$311.8K$627.9K51
2023Gregory A. Demopulos, M.D.President, Chief Executive Officer and Chairman of the Board$917.3K$7.7M51
2023Peter B. Cancelmo, J.D.Vice President, General Counsel and Secretary$456.5K$852.6K51

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.6,044,633$57.5M0.0%+735,007
UBS Group AG3,148,384$29.9M0.0%+807,653
Vanguard Capital Management LLC3,072,050$29.2M0.0%+88,791
State Street Corp2,319,906$22.1M0.0%+400,331
Geode Capital Management, LLC1,914,460$18.2M0.0%+162,137
Stifel Financial Corp1,836,925$17.5M0.0%+5,340
Vanguard Portfolio Management LLC962,828$9.2M0.0%+244,153
Invesco Ltd.751,771$7.1M0.0%+571,142
Northern Trust Corp727,348$6.9M0.0%+163,481
Rock Springs Capital Management LP718,499$6.8M0.3%New
Corient Private Wealth LP659,730$6.3M0.0%−141,681
Rubric Capital Management LP656,874$6.2M0.1%New
Charles Schwab Investment Management Inc604,633$5.8M0.0%+22,121
Bank Of Montreal /can/568,424$5.4M0.0%−2
Vanguard Fiduciary Trust Co491,173$4.7M0.0%−1,172
Federated Hermes, Inc.478,290$4.5M0.0%New
Clutterbuck Capital Management LLC450,000$4.3M2.5%+150,000
Two Sigma Investments, LP402,662$3.8M0.0%+116,188
Morgan Stanley394,459$3.8M0.0%+76,567
Millennium Management LLC343,839$3.3M0.0%−66,770
Susquehanna International Group, Llp325,194$3.1M0.0%−159,836
Badgley Phelps Wealth Managers, LLC263,556$2.5M0.0%No change
Wellington Management Group Llp204,541$1.9M0.0%+17,241
Bank of New York Mellon Corp195,990$1.9M0.0%+29,744
Bank Of America Corp /de/194,140$1.8M0.0%−10,665

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How OMEROS CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROMEROS CORP1
  • CIK0001285819
  • Employer ID (EIN)91-16637414
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inWashington4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address201 Elliott Avenue West, Seattle, WA 981191
  • Phone206-676-50001
  • Shares outstanding72,388,316 as of Aug 7, 20269
  • Public float$172.4M as of Jun 30, 20254
  • AuditorErnst & Young LLP, Seattle, Washington PCAOB ID 42; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMar 31, 20041
  • Filings808 in all: 4 (276), 8-K (180), 10-Q (51), SC 13G/A (47), 424B5 (28), CT ORDER (27), 10-K (17), 3 (17)1
    All 40 form types

    DEF 14A (17), SC 13G (16), 144 (15), S-8 (14), UPLOAD (12), ARS (10), CORRESP (9), REGDEX/A (9), 424B3 (7), EFFECT (6), S-1/A (6), SCHEDULE 13G/A (5), FWP (4), REGDEX (4), S-3ASR (4), POS AM (3), POSASR (3), S-3 (3), 10-K/A (2), D (2), RW (2), S-1 (2), 305B2 (1), 4/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), AW (1), CERTNAS (1), DEFA14A (1), NO ACT (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) Apr 30, 2026
    Latest 8-K (8-K) Aug 13, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.01 per shareOMERNasdaq

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks OMEROS CORP names in Item 1A of its 10-K filed Mar 31, 2026: 38 risks under these headings, as written.4

  • Risks Related to Our Products, Product Candidates, Programs and Operations
  • Our ability to achieve profitability is highly dependent on the commercial success of YARTEMLEA, and to the extent YARTEMLEA is not successful, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline.
  • If YARTEMLEA or any other product that we develop and commercialize does not receive adequate coverage or reimbursement from governments and/or private payers our prospects for revenue and profitability would suffer.
  • Our ability to realize further value from zaltenibart depends on the development and commercialization efforts of Novo Nordisk.
  • We have incurred cumulative operating losses since inception. If we are unable to raise additional capital when needed, we may be unable to complete the development and commercialization of our products and product candidates or to continue our other preclinical development programs.
  • Our indebtedness and liabilities and any future indebtedness could limit the cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operations.
  • Failure to obtain and maintain regulatory approval in the EU or other foreign jurisdictions would prevent us from commercializing and marketing YARTEMLEA or future commercialized products.
  • We may face a variety of risks associated with international operations that, if realized, could materially adversely affect our business.
  • Our operating results are unpredictable and may fluctuate.
  • Significant changes to the size, structure, powers and operations of the U.S. federal government, as well as policy actions by the U.S. federal government, may cause economic disruptions or changes in the regulatory environment that could, in turn, adversely impact our business, results of operations and financial condition.
  • We are subject to extensive government regulation and the failure to comply with these regulations may have a material adverse effect on our operations and business.
  • Failure to comply with any YARTEMLEA post-marketing requirement or commitment could materially adversely affect the commercial prospects of YARTEMLEA and our business.
The other 27 risks
  • We may face difficulties from changes to current regulations as well as future legislation.
  • We have no internal capacity to manufacture commercial or clinical supplies of YARTEMLEA or our product candidates, intend to continue to rely solely on third-party manufacturers, and thus may be materially harmed by issues impacting our contract manufacturers or our relationship with our contract manufacturers.
  • Ingredients, excipients, test kits and other materials necessary to manufacture YARTEMLEA or our product candidates may not be available on commercially reasonable terms, or at all, which may adversely affect sales of YARTEMLEA or development and commercialization of our product candidates.
  • If our clinical trials or clinical protocols are delayed, suspended or terminated, we may be unable to develop our product candidates on a timely basis, which would adversely affect our ability to obtain regulatory approvals, increase our development costs and delay or prevent commercialization of approved products.
  • Because we have a number of product candidates and development programs, we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications for which there is a greater likelihood of obtaining regulatory approval and that may be more profitable, if approved.
  • Our obligations under the Transition Services Agreement require us to utilize significant internal resources that could otherwise be used to advance our other programs.
  • Our product candidates may not successfully complete clinical development or be suitable for successful commercialization or generation of revenue through partnerships, and our preclinical programs may not produce product candidates that are suitable for clinical trials.
  • We may incur substantial costs as a result of commercial disputes, claims, litigation or other legal proceedings relating to our business operations, especially with regard to patent and other intellectual property rights, and such costs or an adverse outcome in such a proceeding may adversely affect our financial condition, results of operations and/or stock price.
  • It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.
  • Novo Nordisk controls significant aspects of the prosecution, maintenance, and enforcement of key intellectual property covering zaltenibart products, and its failure to protect, enforce, or maintain that intellectual property could adversely affect the commercial value of zaltenibart products and, in turn, the milestone or royalty payments we receive.
  • Competitors may develop products that are less expensive, safer or more effective, or which may otherwise diminish or eliminate the success of any products that we may commercialize.
  • The loss of members of our management team could substantially disrupt our business operations.
  • We rely on highly skilled personnel and, if we are unable to retain or motivate key personnel or hire qualified personnel, we may not be able to maintain our operations or grow effectively.
  • We may encounter difficulties managing our growth, which could delay our business plans or adversely affect our results of operations.
  • Product liability claims may damage our reputation and, if insurance proves inadequate, these claims may harm our business.
  • We rely on third parties to conduct portions of our preclinical research and clinical trials. If these third parties do not perform as contractually required or otherwise expected, or if we fail to adequately supervise or monitor these parties, we may not be able to obtain regulatory approval for or commercialize our product candidates.
  • If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.
  • Our use of artificial intelligence exposes us to deficient outputs, unintentional disclosures, and an evolving regulatory landscape.
  • The availability of royalties from Rayner is dependent on Rayner’s net sales of OMIDRIA and may be of lesser magnitude than anticipated or may not become payable at all and we do not expect to receive a sales-based milestone payment from DRI.
  • As a non-accelerated filer, we are not required to comply with the auditor attestation requirements of the Sarbanes-Oxley Act.
  • General Risk Factors Related to our Business
  • Cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations.
  • Our stock price has been and may continue to be volatile, and the value of an investment in our common stock may decline.
  • If we issue additional shares of our common stock or other securities that may be convertible into, or exercisable or exchangeable for, our common stock, our existing shareholders would experience further dilution.
  • If we or the third parties upon whom we rely are adversely affected by natural disasters or other events, our business continuity and disaster recovery plans may not adequately protect us from such interruptions.
  • Anti-takeover provisions in our charter documents and under Washington law could make an acquisition of us, which may be beneficial to our shareholders, difficult and prevent attempts by our shareholders to replace or remove our current management.
  • We have never declared or paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes to offset taxable income or taxes may be limited.

Legal proceedings

From time to time, in the ordinary course of business, we may be involved in various claims, lawsuits and other proceedings. As of the date of filing of this Annual Report on Form 10-K, we were not involved in any material legal proceedings.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51